GLP-1 microdosing: what it means

If you have spent any time in weight-loss forums this year, you have probably seen the word “microdosing” applied to GLP-1 medications like semaglutide and tirzepatide. It sounds precise and scientific, but the term is doing a lot of quiet work, and much of it is unearned. This page explains what people actually mean by it, what the evidence says, and, importantly, the difference between a doctor tailoring a dose within the approved framework and the self-directed “microdosing” being sold online.

What does “microdosing” a GLP-1 mean?

“Microdosing” a GLP-1 generally means taking a dose lower than the standard FDA-approved regimen: sometimes a fraction of a normal dose, and sometimes small amounts taken more often than the usual once-weekly injection. There is no single agreed-upon definition. As one obesity-medicine physician put it, “Microdosing is not a medical term. It’s a term that has been popularized on social media” (Cedars-Sinai). Some companies “define it arbitrarily as 25% of a standard dose, even though there’s no ‘standard dose’ for GLP-1s” (Cedars-Sinai).

That vagueness matters. FDA-approved GLP-1 products come in specific, labeled doses that are stepped up on a defined schedule. “Microdosing,” by contrast, usually refers to non-standard amounts, and in practice it is often tied to compounded products that fall outside those approved GLP-1 therapies (STAT).

Why do people try it?

People reach for the idea for understandable reasons: to spend less, to blunt the nausea and other gastrointestinal side effects that can come with GLP-1s, or to hold onto weight they have already lost without staying on a full dose. Those goals are legitimate. The problem is not the motivation: it is that “microdosing” as marketed is not a validated way to achieve them, and some versions of it carry real risks.

Is microdosing an approved way to take a GLP-1?

No. Microdosing is not an FDA-approved dosing strategy for semaglutide or any other GLP-1 medication. Using an approved drug at a non-standard dose is off-label use, which a licensed clinician may choose when they judge it medically appropriate, but that is a supervised medical decision, not a product you can order to a fixed “micro” protocol. When microdosing relies on compounded semaglutide or tirzepatide, the product itself is not FDA-approved either, and the FDA does not review compounded drugs for safety, effectiveness or quality before they are sold (FDA, concerns with unapproved GLP-1 drugs used for weight loss). For what compounded semaglutide is and how it compares with the brands, see our compounded semaglutide explainer.

Is there evidence that microdosing works?

Not for weight loss. The randomized trials behind GLP-1 approvals studied specific doses on specific schedules, not “micro” amounts, and there are no clinical trials, safety studies, or official recommendations validating microdosing. As one specialist summarized, “We don’t have any evidence that low-dose, intermittent use of GLP-1s provides meaningful or sustained weight loss or broader health benefits” (Cedars-Sinai). Reporting on the trend reaches the same conclusion: “There are no legitimate long-term data to support it,” and none of the compounded products commonly used for it “have been studied either short or long term for safety, efficacy, or weight regain after stopping them” (STAT).

Is it safe?

The honest answer is that no one can promise it is, because it has not been studied. Beyond the lack of proven benefit, clinicians point to the risks of using an unstudied dose and, when compounded products are involved, of uncertain contents. Compounded medications “are not subject to the same rigorous testing,” and a user “may not even know exactly what you’re getting” (Cedars-Sinai). Another physician put the uncertainty bluntly: “There’s no guarantee that these small doses won’t cause big problems” (STAT).

Measuring is a practical risk too. Small, non-standard doses are usually drawn by hand from a multi-dose vial, and the FDA has received adverse event reports, some requiring hospitalization, that may be linked to dosing errors with compounded semaglutide, where patients or clinicians got the amount wrong (FDA). The FDA’s advice for anyone using such a vial is to discard it 28 days after first use and to use a new sterile needle and syringe for every dose.

A low dose from a doctor is not the same thing

This is the distinction that gets lost. GLP-1 medications are deliberately started low and increased slowly. Wegovy, for example, begins at 0.25 mg once weekly and is titrated upward over months to limit side effects, with a maintenance dose reached on a defined schedule (Wegovy prescribing information, DailyMed). A clinician may also hold you at a lower step, slow your titration, or individualize your plan for tolerability, all within the approved framework and under monitoring. That supervised dose-tailoring is fundamentally different from buying a “microdose” protocol off a website. If you want the mechanics of how approved dosing actually works, see GLP-1 dosing and titration explained, and for how side effects are managed as the dose is raised, our main GLP-1 guide walks through the process.

The bottom line

“Microdosing” is a marketing-and-forum word, not a proven regimen. There is no evidence that low, non-standard GLP-1 doses deliver meaningful or lasting weight loss, it is not a strategy the FDA has approved, and when it leans on compounded products it adds dosing and quality uncertainty on top. The goals people chase with it (lower cost, fewer side effects, holding steady after weight loss) are real, and the right way to pursue them is an individualized, monitored plan with a licensed provider. If your interest in a lower dose is about maintaining your results, it is worth understanding first what happens when you stop a GLP-1.